Eli Lilly Just Announced Fantastic News for Shareholders

Eli Lilly reported continued explosive GLP-1 growth, with Mounjaro revenue up 125% to $8.6 billion and Zepbound revenue up 80% to $4.1 billion in the recent quarter. Its newly launched oral weight loss pill, Foundayo, has already reached 20,000 patients, 80% of them new to the class, and offers an advantage over Novo Nordisk's oral Wegovy by not requiring empty-stomach dosing. The update supports further market-share gains and suggests another leg of growth for Lilly's obesity franchise.

Analysis

The market is still underestimating the shift from a single-product obesity story to a platform expansion story. The pill format matters less as a convenience feature than as a funnel-expansion tool: it widens the addressable population to needle-averse patients and primary-care prescribers who were never going to push injectables, which should sustain share gains even if the class broadens. That makes the near-term debate less about peak demand and more about whether Lilly can keep converting new prescribers faster than competitors can compress pricing.

The second-order effect is pressure on the competitive moat through access economics, not just efficacy. If the oral formulation materially lowers friction, payers may see stronger adherence and fewer drop-offs, which can improve real-world outcomes and strengthen formulary positioning versus peers. That can also force rivals into a more aggressive rebate cycle, especially if their oral offerings require stricter dosing conditions or generate more patient friction, which would erode industry margins before it shows up in headline market-share data.

The main risk is that the trade has shifted from “can Lilly win?” to “how much is already in the stock?” The next several quarters should be strong on revenue, but the stock can still stall if the market concludes the growth slope is decelerating from hyper-growth to merely excellent growth. Watch for any signal that oral uptake is cannibalizing higher-margin injectable demand faster than it adds new patients, because that would cap multiple expansion even if topline keeps beating.

Contrarian takeaway: the biggest misread is likely on Novo and the smaller pipeline names, not Lilly. This launch raises the bar for competitors by turning convenience into a measurable commercial advantage, which means the market may be too generous on future share recovery assumptions for oral alternatives. The implied winners are wholesalers, specialty pharmacies, and adherence-linked service providers, which should see higher throughput if the class keeps expanding beyond early adopters.

Key Decisions for Investors

• Stay long LLY on 1-3 month horizon, but use call spreads rather than stock to avoid multiple compression risk; prefer 12/13-month upside exposure if the launch data continues to show >70% new-to-class patients.
• Short NVO vs long LLY as a pair trade for the next 1-2 quarters; thesis is convenience-led share erosion and pricing pressure, with upside if oral adoption inflects faster than consensus expects.
• Avoid chasing VKTX here; use rallies to fade into any obesity-beta speculation, since the bar for differentiated oral convenience just moved materially higher.
• Sell cash-secured puts on LLY on any post-earnings weakness; the stock should retain a premium bid from execution visibility, but the implied vol likely overstates near-term downside after a clean launch read-through.